
Magnitude Biosciences, a specialist contract research organisation, has secured €1.5 million in funding.
The investment will accelerate the commercialisation of VivoScanTM, its proprietary in vivo high-throughput screening platform.
Key Takeaways
Center
Coverage blindspot: Reporting on this development is currently concentrated in other segments of the media landscape.
Coverage blindspot: Reporting on this development is currently concentrated in other segments of the media landscape.
Get every side of the week's biggest story in your inbox.
Potential to advance drug discovery and development
No attributed perspective yet — we only show quotes grounded in analysis.
Evaluated across 1 reporting source (0% Left · 100% Center · 0% Right)
Historical editorial baseline for EU-Startups
Multi-factor accuracy index for EU-Startups and related desks based on verifiable sourcing and editorial standards.
Factuality: High 100%
Ownership: EU-Startups (Corporate)
Public conversation related to this story
Loading comments…